-+ 0.00%
-+ 0.00%
-+ 0.00%

MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors

Benzinga·04/10/2026 12:35:14
Listen to the news

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults

CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability.